Civica signs up Profil to run trials for affordable insulin biosimilars
Civica Rx has chosen Germany-based CRO Profil to run clinical trials for its “affordable insulin” candidates.
All Posts in "News Team"
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor
Merck KGaA’s North American healthcare business, EMD Serono, is discontinuing a clinical trial for a med once considered a star in its oncology program, but an interim analysis has the company changing tactics.
Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy
A device that’s meant to clear out and expand the lungs may actually go too far, resulting in a potentially dangerous decrease in overall oxygen levels, Baxter said this week.
Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise
This could be good news, or bad news. Amylyx Pharmacueticals has received notice from the FDA that the decision date for its amyotrophic lateral sclerosis drug has been extended.
Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom
Qiming Venture Partners appears to be living up to its name—which translates to enlightened in Chinese—closing out an oversubscribed $260 million financing round and adding a former biotech CEO to its panel of partners that leads the company.
Why the war in Ukraine might make root canals more difficult
Russia’s assault on Ukraine is being felt worldwide, and the U.S. healthcare system is not immune.
ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis
Fresh off the FDA’s clearance for its latest continuous glucose monitor, the FreeStyle Libre 3, Abbott is already attempting to one-up itself.
BD launches advanced flow cytometry system that sorts cells based on their inner workings
BD will begin rolling out its latest technology for sorting and characterizing the myriad cells that make up the human body, with a speed and clarity that the company says could help identify new types of cells and the roles they play in life and disease.
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect
Biogen is back with a fresh cut of data on its antisense amyotrophic lateral sclerosis (ALS) candidate, pooling the results of a failed phase 3 and an open-label extension in an attempt to find a way forward for the Ionis Pharmaceuticals-partnered prospect.
In a rare rebuke, FDA refuses to fully review Aeglea’s rare disease drug application
The FDA has no plans to make a decision on whether Aeglea BioTherapeutics’ rare disease drug is approvable, at least not until the company turns over clinical data that demonstrate a treatment effect.
Weekly Market Review – June 25, 2022
Civica signs up Profil to run trials for affordable insulin biosimilars
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor
Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy
Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise
Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom
Why the war in Ukraine might make root canals more difficult
ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis
BD launches advanced flow cytometry system that sorts cells based on their inner workings
After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect